Sandoz Gliclazide MR · DIN 02461323 · 30 mg · extended release tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-31 — choose a marketed DIN from the same-category list.Discontinued July 31, 2026 · checked November 17, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-31 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-07-31 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Gliclazide MR · DIN 02461323
Manufacturer: Sandoz Canada Inc.; listing date 2020-07-31
Health Canada: Cancelled post market since 2026-07-31 · brand SANDOZ GLICLAZIDE MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 30 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Gliclazide MR: Formulary list price $0.09 per unit (the source does not state the unit; exact figure $0.0931). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02461323)
Source record
DIN 02461323: Sandoz Gliclazide MR
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002025; group id 745; item number 1824; lccId None; manufacturer id SDZ
Source form: SR Tab; strength: 30mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.0931; ministry $0.0931
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02461323
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94883
Interchangeable products
Apo-Gliclazide MR · DIN 02297795 · $0.0931
Diamicron MR · DIN 02242987 · $0.0931
Gliclazide MR · DIN 02524856 · $0.0931
Jamp Gliclazide MR · DIN 02429764 · $0.0931
Mint-Gliclazide MR · DIN 02423286 · $0.0931
Mylan-Gliclazide MR · DIN 02438658 · $0.0931
Taro-Gliclazide MR · DIN 02463571 · $0.0931
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since July 31, 2026 — choose a marketed DIN from the same-category list.